1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117:313–319.e1.
Article
2. Silva RM, Faria de Abreu JR, Cunha-Vaz JG. Blood-retina barrier in acute retinal branch vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1995; 233:721–726.
Article
3. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006; 244:309–315.
Article
4. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008; 16:791–799.
Article
5. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008; 92:518–522.
Article
6. Kondo M, Kondo N, Ito Y, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina. 2009; 29:1242–1248.
7. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009; 93:452–456.
8. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114:855–859.
Article
9. Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology. 2011; 118:1827–1833.
Article
10. Pinna A, Blasetti F, Ricci GD, Boscia F. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol. 2017; 27:326–330.
Article
11. Li S, Hu A, Wang W, et al. Combinatorial treatment with topical NSAIDs and anti-VEGF for age-related macular degeneration, a meta-analysis. PLoS One. 2017; 12:e0184998.
Article
12. Wyględowska-Promieńska D, Piotrowska-Gwóźdź A, Piotrowska-Seweryn A, Mazur-Piotrowska G. Combination of aflibercept and bromfenac therapy in age-related macular degeneration: a pilot study aflibercept and bromfenac in AMD. Med Sci Monit. 2015; 21:3906–3912.
Article
13. Shimura M, Yasuda K. Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion. Br J Ophthalmol. 2015; 99:215–219.
Article
14. Hayreh SS, Zimmerman MB. Fundus changes in branch retinal vein occlusion. Retina. 2015; 35:1016–1027.
Article
15. Munk MR, Sacu S, Huf W, et al. Differential diagnosis of macular edema of different pathophysiologic origins by spectral domain optical coherence tomography. Retina. 2014; 34:2218–2232.
Article
16. Abri Aghdam K, Reznicek L, Soltan Sanjari M, et al. Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion. Int J Ophthalmol. 2016; 9:858–862.
Article
17. Finkelstein D. Argon laser photocoagulation for macular edema in branch vein occlusion. Ophthalmology. 1986; 93:975–977.
Article
18. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009; 127:1115–1128.
19. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005; 140:256–261.
Article
20. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009; 50:1025–1032.
Article
21. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117:1102–1112.e1.
22. Varma R, Bressler NM, Suñer I, et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012; 119:2108–2118.
23. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011; 118:1594–1602.
Article
24. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012; 119:802–809.
25. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN study. Ophthalmology. 2014; 121:209–219.
26. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015; 122:538–544.
27. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010; 21:178–183.
Article
28. Gomi F, Sawa M, Tsujikawa M, Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina. 2012; 32:1804–1810.
Article
29. Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008; 24:392–398.
Article
30. Yoshinaga N, Arimura N, Otsuka H, et al. NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway. Lab Invest. 2011; 91:1277–1290.
Article